Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday (May 13, 2025), helped by strong demand for its drugs used to treat chronic ...

Cipla is facing moderate headwinds at the moment. India business underwent a soft two quarters, US business faced supply issues in one main product and Trump tariff pressure has impacted the ...

Cipla shares gained over 2 percent on December 17 after Kotak Institutional Equities upgraded the stock to a 'buy' from its previous 'add' rating. The upgrade was driven by factors such as ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

Cipla share price fell the most in terms of percentage among all the 50 companies in the NSE Nifty today Cipla share price: Cipla Ltd shares fell the most in terms of percentage among all the 50 ...

Drugmaker Cipla continues to struggle with regulatory challenges which have caused delays in the launch of two key drugs--respiratory medication Advair and chemotherapy drug Abraxane- yet again.

Oct 29 (Reuters) - Cipla (CIPL.NS), opens new tab, India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat estimates, driven by higher sales of ...

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection ...

Cipla Limited on Thursday announced that it has signed definitive agreements for further investment of up to approximately Rs. 26 crore in Optionally Convertible Preference Shares of Achira Labs ...

Cipla Health Limited is wholly-owned subsidiary of Cipla (Image Credits: PTI) Cipla Limited on Monday received approval from the Central Drugs Standard Control Organization (CDSCO) to market the ...